Akari Therapeutics Stock (NASDAQ:AKTX)
Previous Close
$2.31
52W Range
$1.08 - $4.40
50D Avg
$2.71
200D Avg
$2.55
Market Cap
$27.81M
Avg Vol (3M)
$15.80K
Beta
0.95
Div Yield
-
AKTX Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.